The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Omnicell met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased, and earnings per share expanded significantly.
Margins improved across the board.
Omnicell booked revenue of $62.9 million. The six analysts polled by S&P Capital IQ expected sales of $63.2 million. Sales were 9.9% higher than the prior-year quarter's $57.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $0.19. The six earnings estimates compiled by S&P Capital IQ averaged $0.16 per share on the same basis. GAAP EPS of $0.12 for Q4 were 492% higher than the prior-year quarter's $0.02 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 57.0%, 220 basis points better than the prior-year quarter. Operating margin was 9.8%, 710 basis points better than the prior-year quarter. Net margin was 6.6%, 540 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $64.8 million. On the bottom line, the average EPS estimate is $0.15.
Next year's average estimate for revenue is $275.4 million. The average EPS estimate is $0.71.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 160 members out of 170 rating the stock outperform, and 10 members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 51 give Omnicell a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Omnicell is buy, with an average price target of $19.67.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Omnicell the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Omnicell to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.